Macrophage‐based delivery of anti‐fibrotic proteins alleviates bleomycin‐induced pulmonary fibrosis in mice

Idiopathic pulmonary fibrosis (IPF) is a fatal interstitial lung disease characterized by chronic, progressive, and fibrotic injury. Although remarkable progress has been made toward understanding the pathogenesis of PF, finding more effective treatments for this remains challenge. In study, we describe an innovative macrophage-based approach to deliver anti-fibrotic protein inhibit PF in mouse model bleomycin (BLM)-induced We engineered macrophages continuously secrete three types proteins: interleukin-10, which prevents inflammation; TGFRcFc, soluble truncated TGF-βR2 that blocks TGF-β; CD147, induces matrix metalloproteinases (MMPs) causes collagen degradation. Infusing these into lungs BLM-induced models optimal pattern significantly ameliorated mice. Specifically, most therapeutic outcome was achieved infusing IL-10-secreting on day 1, followed TGFRcFc-secreting 7 CD147-secreting 14 same mice after BLM treatment. Our data suggest delivery proteins promising therapy disorders.